PaxSafe's Mark Talens on why pharma supply chain AI fails before it starts — and the data foundry framework that changes that.
|Articles|August 17, 2016
Recordati Makes New Appointments Following Death of CEO
August 17, 2016
Advertisement
Following the death of its Chairman and Chief Executive Officer Giovanni Recordati this week, the board of Recordati (Milan, Italy) appointed Alberto Recordati as Chairman of the Board of Directors and Andrea Recordati as Vice Chairman and Chief Executive Officer.
Andrea has been Chief Operating Officer since 2013, in charge of the group’s commercial and production activities. Alberto Recordati has been responsible for drug discovery and development activities since 2008 and for licensing-in activities since 2011.
Giovanni Recordati had been Chief Executive Officer of the company since 1990.
Advertisement
Related to this article
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Why purpose is becoming the most important infrastructure in AI-driven health care technology.
Advertisement
Advertisement
Trending on PharmExec
1
AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion
2
The Impact That the Renewed Focus on Domestic Manufacturing Might Have on the Supply Chain
3
FDA Launches Rare Disease Framework Initiative
4
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
5